Neuronetics Stock Performance

STIM Stock  USD 3.60  0.34  8.63%   
Neuronetics holds a performance score of 15 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 2.13, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuronetics will likely underperform. Use Neuronetics downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to analyze future returns on Neuronetics.

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Neuronetics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, Neuronetics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
4.23
Five Day Return
(1.50)
Year To Date Return
164.43
Ten Year Return
(85.82)
All Time Return
(85.82)
JavaScript chart by amCharts 3.21.151234567891011122025FebMar 050100150200250
JavaScript chart by amCharts 3.21.15Neuronetics Neuronetics Dividend Benchmark Dow Jones Industrial
1
Insider Trading
01/27/2025
2
Industry Analysts Just Made A Dazzling Upgrade To Their Neuronetics, Inc. Revenue Forecasts
02/10/2025
3
Disposition of 17307 shares by Furlong Stephen of Neuronetics at 4.11 subject to Rule 16b-3
02/14/2025
4
Disposition of 25934 shares by Keith Sullivan of Neuronetics at 4.41 subject to Rule 16b-3
02/18/2025
5
Disposition of 24440 shares by Keith Sullivan of Neuronetics at 4.7 subject to Rule 16b-3
02/19/2025
6
Acquisition by Furlong Stephen of 78750 shares of Neuronetics subject to Rule 16b-3
02/24/2025
7
Neuronetics Inc Q4 2024 Earnings Report Preview What To Look For
03/03/2025
8
Neuronetics Inc Q4 2024 Earnings Revenue Surpasses Estimates at 22. ...
03/04/2025
9
Neuronetics Inc Q4 2024 Earnings Call Highlights Revenue Growth Amidst Rising Expenses ...
03/05/2025
10
Neuronetics, Inc.s Shares Leap 69 percent Yet Theyre Still Not Telling The Full Story
03/06/2025
11
Neuronetics SWOT analysis merger synergies boost growth prospects for stock - Investing.com
03/12/2025
12
Even though Neuronetics has lost US30m market cap in last 7 days, shareholders are still up 130 percent over 5 years
04/02/2025
Begin Period Cash Flow59.7 M
  

Neuronetics Relative Risk vs. Return Landscape

If you would invest  149.00  in Neuronetics on January 3, 2025 and sell it today you would earn a total of  211.00  from holding Neuronetics or generate 141.61% return on investment over 90 days. Neuronetics is currently generating 1.8333% in daily expected returns and assumes 9.3176% risk (volatility on return distribution) over the 90 days horizon. In different words, 83% of stocks are less volatile than Neuronetics, and 64% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
JavaScript chart by amCharts 3.21.15CashMarketSTIM 0246810 0.00.51.01.52.0
       Risk  
Given the investment horizon of 90 days Neuronetics is expected to generate 9.27 times more return on investment than the market. However, the company is 9.27 times more volatile than its market benchmark. It trades about 0.2 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.08 per unit of risk.

Neuronetics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuronetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neuronetics, and traders can use it to determine the average amount a Neuronetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1968

Best PortfolioBest Equity
Good Returns
Average ReturnsSTIM
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 9.32
  actual daily
83
83% of assets are less volatile

Expected Return

 1.83
  actual daily
36
64% of assets have higher returns

Risk-Adjusted Return

 0.2
  actual daily
15
85% of assets perform better
Based on monthly moving average Neuronetics is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neuronetics by adding it to a well-diversified portfolio.

Neuronetics Fundamentals Growth

Neuronetics Stock prices reflect investors' perceptions of the future prospects and financial health of Neuronetics, and Neuronetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neuronetics Stock performance.
Return On Equity-1.33
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-2,500%-2,000%-1,500%-1,000%-500%0%
Return On Asset-0.17
Profit Margin(0.58) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%100%
Operating Margin(0.48) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%
Current Valuation312.74 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-70%-60%-50%-40%-30%-20%-10%
Shares Outstanding65.81 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150,000%100,000%150,000%200,000%250,000%
Price To Book8.98 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-400,000%-300,000%-200,000%-100,000%
Price To Sales3.46 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%10,000%20,000%30,000%40,000%
Revenue74.89 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%100%120%
Gross Profit54.76 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%
EBITDA(34.04 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%
Net Income(43.2 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%
Cash And Equivalents73.7 M
Cash Per Share2.71 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%
Total Debt27.48 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%
Debt To Equity0.63 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,500%-1,000%-500%0%
Current Ratio4.02 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%
Book Value Per Share0.50 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%0%
Cash Flow From Operations(31 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%
Earnings Per Share(1.38) X
Market Capitalization259.31 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-20%-15%-10%-5%
Total Asset140.9 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%
Retained Earnings(419.79 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%100%120%140%
Working Capital26.86 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31

About Neuronetics Performance

By examining Neuronetics' fundamental ratios, stakeholders can obtain critical insights into Neuronetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Neuronetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 74.80  96.19 
Return On Tangible Assets(0.42)(0.44)
Return On Capital Employed(0.32)(0.33)
Return On Assets(0.31)(0.32)
Return On Equity(1.56)(1.48)

Things to note about Neuronetics performance evaluation

Checking the ongoing alerts about Neuronetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neuronetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Neuronetics is way too risky over 90 days horizon
Neuronetics appears to be risky and price may revert if volatility continues
Neuronetics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 74.89 M. Net Loss for the year was (43.2 M) with profit before overhead, payroll, taxes, and interest of 54.76 M.
Neuronetics currently holds about 73.7 M in cash with (31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71.
Latest headline from simplywall.st: Even though Neuronetics has lost US30m market cap in last 7 days, shareholders are still up 130 percent over 5 years
Evaluating Neuronetics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Neuronetics' stock performance include:
  • Analyzing Neuronetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neuronetics' stock is overvalued or undervalued compared to its peers.
  • Examining Neuronetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Neuronetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neuronetics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Neuronetics' stock. These opinions can provide insight into Neuronetics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Neuronetics' stock performance is not an exact science, and many factors can impact Neuronetics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Neuronetics is a strong investment it is important to analyze Neuronetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuronetics' future performance. For an informed investment choice regarding Neuronetics Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.38)
Revenue Per Share
2.36
Quarterly Revenue Growth
0.107
Return On Assets
(0.17)
Return On Equity
(1.33)
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.